key: cord-0819046-qp5xcmsr
authors: Cunningham, Jonathan W.; Claggett, Brian L.; Jering, Karola S.; Vaduganathan, Muthiah; Bhatt, Ankeet S.; Rosenthal, Ning; Solomon, Scott D.
title: Prognostic Value of Natriuretic Peptides and Cardiac Troponins in COVID-19
date: 2021-05-17
journal: Circulation
DOI: 10.1161/circulationaha.121.054969
sha: e804d26fd3e6d2eb328438a6023f1e0835e2af38
doc_id: 819046
cord_uid: qp5xcmsr

nan

Despite modest levels in most patients with COVID-19, NP and troponin elevation strongly and independently predicted in-hospital death, including in patients without cardiovascular disease. The extent to which biomarker levels reflected preexisting cardiovascular disease or COVID-19 severity is unclear. Potential causes of biomarker elevation in COVID-19 include myocardial injury, stress cardiomyopathy, pulmonary embolism, kidney disease, or cardiopulmonary strain attributable to hypoxemia and sepsis, as observed in acute respiratory distress syndrome. 1, 4 Though biomarkers were obtained for clinical indications, similar adjusted mortality in patients with and without biomarkers suggests minimal residual confounding by indication. Measurement of admission NPs, troponin, or both in COVID-19 patients may help clinicians determine appropriate triage and identify high-risk patients for clinical trials. 

None.

Dr Cunningham is supported by the National Heart, Lung, and Blood Institute (T32 postdoctoral training grant T32HL094301). Dr Claggett reports personal fees from Amgen, Boehringer Ingelheim, Corvia, MyoKardia, and Novartis. Dr Jering is supported by the National Heart, Lung, and Blood Institute (T32 postdoctoral training grant T32HL007604 

Myocardial injury in severe COVID-19 compared with non-COVID-19 acute respiratory distress syndrome. Circulation

Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China

Established cardiovascular biomarkers provide limited prognostic information in unselected patients hospitalized with COVID-19

Prognostic value of plasma N-terminal probrain natriuretic peptide levels in the acute respiratory distress syndrome

for Advancing Translational Sciences Award UL 1TR002541); receives research grant support from Amgen and Boehringer Ingelheim; serves on advisory boards for Amgen, American Regent, AstraZeneca, Baxter Healthcare, Bayer AG, Boehringer Ingelheim, Cytokinetics, and Relypsa; and participates in clinical end point committees for studies sponsored by Galmed, Novartis, and the National Institutes of Health. Dr Bhatt reports speaking fees from Sanofi Pasteur and is supported by the National Heart, Lung, and Blood Institute (T32 postdoctoral training grant T32HL007604). Dr Rosenthal is an employee of Premier Inc, which curates the Premier Healthcare Database. Dr Solomon reports grants from Alnylam, Amgen, AstraZeneca, Bellerophon, Bayer, Bristol Myers Squibb, Celladon, Cytokinetics, Eidos, Gilead, GlaxoS-mithKline, Ionis, Lone Star Heart, Mesoblast, MyoKardia, Neurotronik, National Institutes of Health/National Heart, Lung, and Blood Institute, Novartis, Respicardia, Sanofi Pasteur, and Theracos; and personal fees from Akros, Alnylam, Amgen, Arena, AstraZeneca, Bayer, Bristol Myers Squibb, Cardior, Cardurion, Corvia, Cytokinetics, Daiichi-Sankyo, Gilead, GlaxoSmithKline, Ironwood, Merck, Myokardia, Novartis, Roche, Takeda, Theracos, Quantum Genetics, Cardurion, AoBiome, Janssen, Cardiac Dimensions, Sanofi-Pasteur, Tenaya, Dinaqor, Tremeau, CellProThera, and Moderna.